文献速递精神分裂症与精神病性障碍

精神病预防:临床高危人群的检测、预后与干预进展

Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.
PubMed 文献 · JAMA Psychiatry · 2020-01-01

该系统综述纳入2013至2019年发表的42项Meta分析,评估精神病临床高危(CHR-P)个体的检测、预后与干预证据。CHR-P个体3年精神病风险为22%,简短间歇性精神病症状亚组最高达38%;目前尚无稳健证据支持任一指示性干预优于其他干预,但建议仍提供需求导向和心理干预。

要点

  • CHR-P个体3年精神病风险为22%,简短间歇性精神病症状亚组风险最高为38%。
  • 基线阴性症状(Cohen d=0.35)和衰减精神病症状(Cohen d=0.39)严重度与精神病风险升高相关。
  • 尚无稳健证据支持任一指示性干预优于其他干预,但建议仍提供需求导向和心理干预。

核心结论

  • 该综述确认CHR-P个体检测和预后方面取得实质性进展,但有效指示性干预仍需明确。
  • 证据提示需在初级和二级医疗机构设立专项服务以检测CHR-P个体、用经验证的心理测量工具制定预后并提供需求导向和心理干预。

研究设计与样本

  • 检索Web of Science、Cochrane Central Register of Reviews和Ovid/PsychINFO 2013年1月1日至2019年6月30日发表的CHR-P个体Meta分析,并用MEDLINE检索参考文献。
  • 共纳入过去6年发表的42项Meta分析,涵盖81项结局。

主要发现

  • CHR-P个体平均(SD)年龄20.6(3.2)岁,男性占58%,多表现为衰减精神病症状持续超过1年才就诊专项服务。
  • CHR-P个体物质使用常见(33%吸烟、27%使用大麻),共病精神障碍常见(41%抑郁障碍、15%焦虑障碍),自杀意念66%、自伤49%。
  • CHR-P个体工作功能(Cohen d=0.57)、教育功能(Cohen d=0.21)、社会功能(Cohen d=1.25)和生活质量(Cohen d=1.75)均受损。
  • CHR-P工具在临床样本中预后准确性良好;总体3年精神病风险22%,简短间歇性精神病症状亚组最高38%。
  • 基线衰减精神病症状(Cohen d=0.35)、阴性症状(Cohen d=0.39)严重度和低功能(Cohen d=0.29)与精神病风险升高相关。

关键数值与推荐

  • CHR-P个体3年精神病风险为22%,简短间歇性精神病症状亚组为38%。
  • 基线衰减精神病症状严重度Cohen d=0.35、阴性症状严重度Cohen d=0.39、低功能Cohen d=0.29与精神病风险升高相关。
  • 控制风险富集并实施序贯风险评估可优化预后准确性。
  • 尚无稳健证据支持任一指示性干预(包括需求导向干预和对照条件)优于其他干预以预防精神病或改善其他结局。

临床怎么用

  • 在初级和二级医疗机构设立专项服务以检测CHR-P个体。
  • 使用经验证的心理测量工具制定预后。
  • 提供需求导向和心理干预,尽管指示性干预证据不确定性高。

局限性

  • 指示性干预证据不确定性高,尚无稳健证据支持任一干预优于其他干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Detection, prognosis, and indicated interventions in individuals at clinical high risk for psychosis (CHR-P) are key components of preventive psychiatry. OBJECTIVE: To provide a comprehensive, evidence-based systematic appraisal of the advancements and limitations of detection, prognosis, and interventions for CHR-P individuals and to formulate updated recommendations. EVIDENCE REVIEW: Web of Science, Cochrane Central Register of Reviews, and Ovid/PsychINFO were searched for articles published from January 1, 2013, to June 30, 2019, to identify meta-analyses conducted in CHR-P individuals. MEDLINE was used to search the reference lists of retrieved articles. Data obtained from each article included first author, year of publication, topic investigated, type of publication, study design and number, sample size of CHR-P population and comparison group, type of comparison group, age and sex of CHR-P individuals, type of prognostic assessment, interventions, quality assessment (using AMSTAR [Assessing the Methodological Quality of Systematic Reviews]), and key findings with their effect sizes. FINDINGS: In total, 42 meta-analyses published in the past 6 years and encompassing 81 outcomes were included. For the detection component, CHR-P individuals were young (mean [SD] age, 20.6 [3.2] years), were more frequently male (58%), and predominantly presented with attenuated psychotic symptoms lasting for more than 1 year before their presentation at specialized services. CHR-P individuals accumulated several sociodemographic risk factors compared with control participants. Substance use (33% tobacco use and 27% cannabis use), comorbid mental disorders (41% with depressive disorders and 15% with anxiety disorders), suicidal ideation (66%), and self-harm (49%) were also frequently seen in CHR-P individuals. CHR-P individuals showed impairments in work (Cohen d = 0.57) or educational functioning (Cohen d = 0.21), social functioning (Cohen d = 1.25), and quality of life (Cohen d = 1.75). Several neurobiological and neurocognitive alterations were confirmed in this study. For the prognosis component, the prognostic accuracy of CHR-P instruments was good, provided they were used in clinical samples. Overall, risk of psychosis was 22% at 3 years, and the risk was the highest in the brief and limited intermittent psychotic symptoms subgroup (38%). Baseline severity of attenuated psychotic (Cohen d = 0.35) and negative symptoms (Cohen d = 0.39) as well as low functioning (Cohen d = 0.29) were associated with an increased risk of psychosis. Controlling risk enrichment and implementing sequential risk assessments can optimize prognostic accuracy. For the intervention component, no robust evidence yet exists to favor any indicated intervention over another (including needs-based interventions and control conditions) for preventing psychosis or ameliorating any other outcome in CHR-P individuals. However, because the uncertainty of this evidence is high, needs-based and psychological interventions should still be offered. CONCLUSIONS AND RELEVANCE: This review confirmed recent substantial advancements in the detection and prognosis of CHR-P individuals while suggesting that effective indicated interventions need to be identified. This evidence suggests a need for specialized services to detect CHR-P individuals in primary and secondary care settings, to formulate a prognosis with validated psychometric instruments, and to offer needs-based and psychological interventions.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fusar-Poli P, Salazar de Pablo G, Correll CU, et al. Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. JAMA Psychiatry. 2020. PMID: 32159746. doi:10.1001/jamapsychiatry.2019.4779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。